|
|
Blood, 15 February 2006, Vol. 107, No. 4, pp. 1724-1730.
Prepublished online as a Blood First Edition Paper on October 20, 2005; DOI 10.1182/blood-2005-08-3372.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study
Julio Delgado,
Kirsty Thomson,
Nigel Russell,
Joanne Ewing,
Wendy Stewart,
Gordon Cook,
Stephen Devereux,
Richard Lovell,
Rajesh Chopra,
David I. Marks,
Stephen Mackinnon, and
Donald W. Milligan
From the Birmingham Heartlands Hospital, Birmingham; Royal Free and University College Hospitals, London; Nottingham City Hospital, Nottingham; St James's University Hospital, Leeds; King's College Hospital, London; Christie Hospital, Manchester; and Bristol Royal Children's Hospital, Bristol, United Kingdom.
We report results in 41 consecutive patients with chronic lymphocytic leukemia (CLL) who underwent allogeneic hematopoietic cell transplantation (HCT) after fludarabine, melphalan, and alemtuzumab conditioning. Donors were 24 HLA-matched siblings and 17 unrelated volunteers, 4 of them mismatched with recipients. All but 3 patients had initial hematologic recovery, but 5 more patients had secondary graft failure. Median intervals to neutrophil (greater than 0.5 x 109/L) and platelet (greater than 20 x 109/L) recovery were 14 days (range, 9-30 days) and 11 days (range, 8-45 days), respectively. Eleven (27%) patients had relapses and received escalated donor lymphocyte infusions, but only 3 of them had sustained responses. Acute and chronic graft-versus-host disease (GVHD) was observed in 17 (41%) and 13 (33%) patients, respectively. Seventeen (41%) patients have died, 5 of progressive disease. The 2-year overall survival and transplantation-related mortality (TRM) rates were 51% (95% confidence interval [CI], 33%-69%) and 26% (95% CI, 14%-46%), respectively. The alemtuzumabbased regimen was feasible and effective in patients with CLL with a relatively low rate of GVHD. However, TRM remains relatively high as a result of a variety of viral and fungal infections. Studies are ongoing to address the efficacy of reduced doses of alemtuzumab in this group of immunosuppressed patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Delgado, D. W. Milligan, and P. Dreger
Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?
Blood,
September 24, 2009;
114(13):
2581 - 2588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Delgado, S. Pillai, N. Phillips, S. Brunet, G. Pratt, J. Briones, R. Lovell, R. Martino, J. Ewing, A. Sureda, et al.
Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis
Ann. Onc.,
July 12, 2009;
(2009)
mdp259v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Farina, C. Carniti, A. Dodero, A. Vendramin, A. Raganato, F. Spina, F. Patriarca, F. Narni, F. Benedetti, A. Olivieri, et al.
Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation
Haematologica,
May 1, 2009;
94(5):
654 - 662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Tam, R. Bassett, C. Ledesma, M. Korbling, A. Alousi, C. Hosing, P. Kebraei, R. Harrell, G. Rondon, S. A. Giralt, et al.
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
Blood,
April 30, 2009;
113(18):
4144 - 4152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Rodrigues, G. Sanz, C. G. Brunstein, J. Sanz, J. E. Wagner, M. Renaud, M. de Lima, M. S. Cairo, S. Furst, B. Rio, et al.
Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
J. Clin. Oncol.,
January 10, 2009;
27(2):
256 - 263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schetelig, A. van Biezen, R. Brand, D. Caballero, R. Martino, M. Itala, J. A. Garcia-Marco, L. Volin, N. Schmitz, R. Schwerdtfeger, et al.
Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis
J. Clin. Oncol.,
November 1, 2008;
26(31):
5094 - 5100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Gribben
The Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia
ASCO Educational Book,
January 1, 2008;
2008(1):
291 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Sorror, B. E. Storer, D. G. Maloney, B. M. Sandmaier, P. J. Martin, and R. Storb
Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia
Blood,
January 1, 2008;
111(1):
446 - 452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Rowe and A. H. Goldstone
How I treat acute lymphocytic leukemia in adults
Blood,
October 1, 2007;
110(7):
2268 - 2275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Brunstein, D. J. Weisdorf, T. DeFor, J. N. Barker, J. Tolar, J.-A. H. van Burik, and J. E. Wagner
Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation
Blood,
October 15, 2006;
108(8):
2874 - 2880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. L. Yee and S. M. O'Brien
Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
August 1, 2006;
81(8):
1105 - 1129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
